Results 21 to 30 of about 6,010 (179)

Microbial challenge test of a novel epoprostenol sodium formulation

Drug Design, Development and Therapy, 2017
Dirk Bandilla,1 Marcel Goverde,2 Paolo Giudici,1 Olivier Lambert1 1Actelion Pharmaceuticals Ltd., Allschwil, 2MGP Consulting GmbH, Binningen, Switzerland Aim: The aim of the current study was to present a comprehensive display of antimicrobial activity
Bandilla D, Goverde M, Giudici P, Lambert O   +3 more
doaj   +1 more source

Cost-Effectiveness of Treprostinil Versus Epoprostenol in Patients with Pulmonary Arterial Hypertension: A Canadian Analysis [PDF]

Canadian Respiratory Journal, 2005
BACKGROUND: Pulmonary arterial hypertension (PAH) is associated with substantial morbidity and mortality, exerting a tremendous health and economic impact on patients.
Thomas R Einarson, John T Granton, Colin Vicente, John H Walker, Greg Engel, Michael Iskedjian   +5 more
doaj   +2 more sources

Transitions From Parenteral Prostacyclin Analogues to Selexipag in Patients With Pulmonary Arterial Hypertension. [PDF]

Pulm Circ
ABSTRACT Pulmonary arterial hypertension (PAH) is a progressive illness that may require therapy with parenteral prostacyclin pathway agents (PPA) (epoprostenol and treprostinil). These parenteral PPA's are continuous ambulatory infusions that require a high level of skill and knowledge to maintain safety and effectiveness.
Kuebel DJ, Collins AR, Jose A, Guido MR, Elwing JM.   +4 more
europepmc   +2 more sources

Association of Pericardial Tamponade With Initiation of Sotatercept in a Patient With Eisenmenger Syndrome. [PDF]

Pulm Circ
ABSTRACT Eisenmenger syndrome (ES) represents an advanced stage of pulmonary arterial hypertension (PAH) associated with congenital heart disease. It is characterized by elevated pulmonary vascular resistance, with a right‐to‐left shunt and resting hypoxemia. ES is associated with high morbidity and mortality.
Aldawsari KA, Simpkin CT, Frank BS, Ivy DD.   +3 more
europepmc   +2 more sources

Portopulmonary hypertension practice patterns after liver transplantation

Liver Transplantation, EarlyView., 2022
Abstract Portopulmonary hypertension (POPH) is a type of pulmonary arterial hypertension occurring exclusively in those with portal hypertensive liver disease. Liver transplantation (LT) can significantly improve outcomes. Current guidelines counsel against immediate adjustments to targeted therapy after LT and suggest routine echocardiography as ...
Arun Jose, Elizabeth J. Kopras, Shimul A. Shah, Jean M. Elwing   +3 more
wiley   +1 more source

Survival Improvement With Steroid Use for Pulmonary Veno-Occlusive Disease With the Aid of Pulmonary Vasodilators and Tyrosine-Kinase Inhibitor, a Retrospective Study. [PDF]

Clin Cardiol
This study aimed to assess the efficacy of steroid treatment with pulmonary vasodilators and tyrosine kinase inhibitors in patients with Pulmonary VenoOcclusive Disease (PVOD). Kaplan‐Meier curve showed that survival of PVOD patients with PSL (PRS) was significantly better with Log rank test (p = 0.01) than without PSL (PNS).
Finger M, Takeuchi K, Kikuchi H, Goda A, Inami T, Tamura Y, Kataoka M, Satoh T.   +7 more
europepmc   +2 more sources

Unexpected Interruptions in the Inhaled Epoprostenol Delivery System: Incidence of Adverse Sequelae and Therapeutic Consequences in Critically Ill Patients

Critical Care Explorations, 2021
OBJECTIVES:. Inhaled epoprostenol is a continuously delivered selective pulmonary vasodilator that is used in patients with refractory hypoxemia, right heart failure, and postcardiac surgery pulmonary hypertension.
Jason M. Block, MD, Jai Madhok, MD, MSE, Clark G. Owyang, MD, Kristen R. Merriman, RRT, MS, Stephen J. Ruoss, MD, Vidya K. Rao, MD, MBA   +5 more
doaj   +1 more source

Lifesaving Compassionate-Use of Sotatercept in a 12-Year-old With Idiopathic Pulmonary Arterial Hypertension. [PDF]

Pulm Circ
ABSTRACT Pediatric idiopathic pulmonary arterial hypertension (IPAH) refractory to maximal medical therapy is associated with high morbidity and mortality, and therapeutic options remain limited. We describe a 12‐year‐old girl with end‐stage IPAH who developed acute decompensated right heart failure despite triple combination therapy, including high ...
Pelczar-Płachta W, Surmacz R, Bobkowski W.   +2 more
europepmc   +2 more sources

Reversible Cardiac Hypertrophy in Pulmonary Arterial Hypertension Treated With High-Dose EpoprostenolNovel Teaching Points

CJC Open, 2022
Although current guidelines recommend the use of prostanoid infusion that includes epoprostenol for high-risk pulmonary arterial hypertension patients, epoprostenol has many adverse effects. We report a case of a heritable pulmonary arterial hypertension
Keiichi Izumi, MD, Takumi Inami, MD, Kaori Takeuchi, MD, Hanako Kikuchi, MD, Ayumi Goda, MD, Masaru Hatano, MD, Takashi Kohno, MD, Konomi Sakata, MD, Junji Shibahara, MD, Kyoko Soejima, MD, Toru Satoh, MD   +10 more
doaj   +1 more source

Survival Into Adulthood With FOXF1-Associated Pulmonary Vascular Disease After Neonatal Onset. [PDF]

Pulm Circ
ABSTRACT Neonates and infants with FOXF1 mutation develop alveolar capillary dysplasia with misalignment of pulmonary veins (ACD/MPV), which is typically considered a uniformly fatal neonatal lung disorder due to marked hypoxemic respiratory failure with severe pulmonary hypertension (PH).
Aldawsari KA, Abman SH, Badesch D, Ivy DD.   +3 more
europepmc   +2 more sources